Carbamazepine Restores Neuronal Signaling, Protein Synthesis, and Cognitive Function in a Mouse Model of Fragile X Syndrome
Open Access
- 7 December 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (23) , 9327
Abstract
Fragile X syndrome (FXS) is a leading genetic disorder of intellectual disability caused by the loss of the functional fragile X mental retardation protein (FMRP). To date, there is no efficacious mechanism-based medication for FXS. With regard to potential disease mechanisms in FXS, it is widely accepted that the lack of FMRP causes elevated protein synthesis and deregulation of neuronal signaling. Abnormal enhancement of the ERK½ (extracellular signal-regulated kinase ½) and PI3K-Akt (Phosphoinositide 3 kinase-protein kinase B) signaling pathways has been identified in both FXS patients and FXS mouse models. In this study, we show that carbamazepine, which is an FDA-approved drug and has been mainly used to treat seizure and neuropathic pain, corrects cognitive deficits including passive avoidance and object location memory in FXS mice. Carbamazepine also rescues hyper locomotion and social deficits. At the cellular level, carbamazepine dampens the elevated level of ERK½ and Akt signaling as well as protein synthesis in FXS mouse neurons. Together, these results advocate repurposing carbamazepine for FXS treatment.Keywords
All Related Versions
Funding Information
- NIH/NIMH (R01MH119149)
- U.S. Department of War (W81XWH-17-1-0270)
This publication has 48 references indexed in Scilit:
- FMRP targets distinct mRNA sequence elements to regulate protein expressionNature, 2012
- FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and AutismCell, 2011
- Hippocampal Focal Knockout of CBP Affects Specific Histone Modifications, Long-Term Potentiation, and Long-Term MemoryNeuropsychopharmacology, 2011
- Fragile X Mental Retardation Protein Regulates Protein Expression and mRNA Translation of the Potassium Channel Kv4.2The Journal of Neuroscience, 2011
- Excess Phosphoinositide 3-Kinase Subunit Synthesis and Activity as a Novel Therapeutic Target in Fragile X SyndromeThe Journal of Neuroscience, 2010
- Intracellular calcium and calmodulin link brain‐derived neurotrophic factor to p70S6 kinase phosphorylation and dendritic protein synthesisJournal of Neuroscience Research, 2009
- The cyclic AMP phenotype of fragile X and autismNeuroscience & Biobehavioral Reviews, 2008
- The Cyclic AMP Cascade Is Altered in the Fragile X Nervous SystemPLOS ONE, 2007
- Distinct regional and subcellular localization of adenylyl cyclases type 1 and 8 in mouse brainNeuroscience, 2007
- The mGluR theory of fragile X mental retardationTrends in Neurosciences, 2004